Supernus Announces Issuance of Third US Patent Protecting Oxtellar XR(R) Read more about Supernus Announces Issuance of Third US Patent Protecting Oxtellar XR(R)
Supernus Announces Resignation of Board Member Read more about Supernus Announces Resignation of Board Member
Supernus Announces FDA Approval of Its Partner's Product, Orenitram(TM) Read more about Supernus Announces FDA Approval of Its Partner's Product, Orenitram(TM)
Supernus Posts Exciting Clinical Data Regarding Trokendi XR(TM) and Oxtellar XR(TM) on the Company Website Read more about Supernus Posts Exciting Clinical Data Regarding Trokendi XR(TM) and Oxtellar XR(TM) on the Company Website
Supernus to Present at Piper Jaffray Healthcare Conference in December Read more about Supernus to Present at Piper Jaffray Healthcare Conference in December
Supernus Pharmaceuticals Reports Third Quarter 2013 Financial Results Read more about Supernus Pharmaceuticals Reports Third Quarter 2013 Financial Results
Supernus Announces Third Quarter 2013 Earnings Conference Call and Webcast Read more about Supernus Announces Third Quarter 2013 Earnings Conference Call and Webcast
Supernus Announces Release of Exciting New Clinical Data on Trokendi XR(TM) Read more about Supernus Announces Release of Exciting New Clinical Data on Trokendi XR(TM)
Supernus Launches Trokendi XR(TM) in the United States Read more about Supernus Launches Trokendi XR(TM) in the United States
Supernus to Present at Two Investor Conferences in September Read more about Supernus to Present at Two Investor Conferences in September